Riad Sherif, MD

Dr. Sherif joined Oculis as CEO in 2017 from Novartis where he served as Entrepreneur in Residence at the Novartis Venture Fund and since 2022, he serves as a member of the BoD for Revenio. Since he took the helm at Oculis, Dr. Sherif raised more than $250 million and the company is now listed on NASDAQ. Furthermore, two successful Phase 2b trials with OCS-01 eye drops in diabetic macular edema (DME) and in inflammation and pain following ocular surgery were completed and two Phase 3 trials in these indications were launched. Most recently, the company announced positive results from these trials including its Stage 1 Phase 3 trial in DME and its Phase 3 trial in inflammation and pain following cataract surgery. Prior to this, he held senior global positions in both Alcon, where he was President of Europe, Middle East and Africa, and Novartis, where he served as President of Novartis Vaccines Latin America and Novartis Pharmaceuticals, Canada. Dr. Sherif joined Novartis Pharmaceuticals in 2002 and has also held roles of increasing seniority. Dr. Sherif is a medical doctor by training, and also has an MBA from IMD and a specialized master’s degree in medical management.